<SEC-DOCUMENT>0001140361-25-041286.txt : 20251110
<SEC-HEADER>0001140361-25-041286.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110083555
ACCESSION NUMBER:		0001140361-25-041286
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		251464567

	BUSINESS ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		303A COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20058659_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:pdsb="http://pdsbiotech.com/20251110" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e0bcc38d2a8a4bc3acdc692cf0ae330e" contextRef="c20251110to20251110" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_5502d1e6007844bc991aa05d7f129030" contextRef="c20251110to20251110">0001472091</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_e54d3a45ce9949d587f75ef1e7efb576" contextRef="c20251110to20251110">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pdsb-20251110.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20251110to20251110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001472091</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-10</xbrli:startDate><xbrli:endDate>2025-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, DC 20549</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 18pt;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_6364f24e2e1641e1a3ccb06a64a841ef" contextRef="c20251110to20251110">8-K</ix:nonNumeric></span></div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Securities Exchange Act of 1934</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_1a08603f19f04a71b4a1d2d6e8944b4e" contextRef="c20251110to20251110" format="ixt:date-monthname-day-year-en">November 10, 2025</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_dd274b78983b49359076c07a6f89b407" contextRef="c20251110to20251110">PDS BIOTECHNOLOGY CORPORATION</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact Name of Registrant as Specified in Charter)</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_69145a50a6174093a14517c915e6c1ab" contextRef="c20251110to20251110" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
                </span></div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a90f95bb935a4873baa78fa1bfc447ac" contextRef="c20251110to20251110">001-37568</ix:nonNumeric><br/>
                </span></div>
            </td>

    <td style="width: 32.96%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_242bc1dc9e8d4b7186efc842e4796bc2" contextRef="c20251110to20251110">26-4231384</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 32.96%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(Commission File Number)</div>
            </td>

    <td style="width: 32.96%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;"> <ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_587ffb2303ea424fade7f064d0d47ab2" contextRef="c20251110to20251110">303A College Road East</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_4b61fc3e787f49f1a931c4ce76b9a457" contextRef="c20251110to20251110">Princeton</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_80e11e4c4ec6486b8574686dfe205d2d" contextRef="c20251110to20251110">NJ</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_41f4b7b9ad6d4d25be9dba57e56aa42d" contextRef="c20251110to20251110">08540</ix:nonNumeric></span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Address of Principal Executive Offices, and Zip Code)</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_b54f2c46de8b4fe9b93f315139cd17b1" contextRef="c20251110to20251110">800</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1b1765365f6a4b4e8e7c7efc1a24685e" contextRef="c20251110to20251110">208-3343</ix:nonNumeric></span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Registrant&#8217;s Telephone Number, Including Area Code</div>

      <div><span style="font-size: 10pt;"><br/>
      </span></div>

      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former Name or Former Address, if Changed Since Last Report)</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
        (<span style="font-family: 'Times New Roman'; font-style: italic;">see</span> General Instruction A.2. below):</div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_29cf338191254c848c70378781b61e94" contextRef="c20251110to20251110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_b250b94f7ab94587bd5ed1fbc2e9dd22" contextRef="c20251110to20251110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_3b0aa04173174dc184247bb5fe005793" contextRef="c20251110to20251110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_db851a4c723e421499620defaa25ebcf" contextRef="c20251110to20251110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 46.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';">Title of each class</div>
            </td>

    <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';">Trading Symbol(s)</div>
            </td>

    <td style="width: 34.28%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Name of each exchange on which</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 46.33%; vertical-align: middle; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_37811586ca634ba096608af85746e495" contextRef="c20251110to20251110">Common Stock, par value $0.00033 per share</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 20%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_89acfbe53ae54e8ca5a2eb660ef84a1b" contextRef="c20251110to20251110">PDSB</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 34.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><span style="-sec-ix-hidden:Fact_e54d3a45ce9949d587f75ef1e7efb576">The Nasdaq Capital Market</span><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule
        12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2 of this chapter).</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_cff6f77327ee463cbea0e2717ec664dd" contextRef="c20251110to20251110" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes &#9744; No &#9744;</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="text-align: left; text-indent: 30pt; margin-left: 12pt; font-family: 'Times New Roman'; font-size: 10pt;">On November 10, 2025, PDS Biotechnology Corporation issued a press release announcing positive clinical and translational data
        presented at the 2025 <span style="font-family: 'Times New Roman'; font-style: italic;">Society for Immunotherapy of Cancer </span>Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical
        activity of the Company&#8217;s investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC.</div>

      <div style="text-align: left; text-indent: 30pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div style="text-align: justify; text-indent: 30pt; font-family: 'Times New Roman'; font-size: 10pt;">A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <span style="font-size: 10pt;"><br/>
        </span></div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(d)</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibits.</div>
              </td>

  </tr>


</table>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 9.84%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.84%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.84%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';"><a href="ef20058659_ex99-1.htm">99.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Press Release Dated November 10, 2025.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9.84%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9.84%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';">104</div>
            </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL Document).</div>
            </td>

  </tr>


</table>
      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt;"><br/>
        </span></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Signature</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned hereunto duly authorized.</div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: center; font-family: 'Times New Roman';">Date: November 10, 2025</div>
            </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><span style="text-decoration: underline;">/s/ Frank Bedu-Addo, Ph.D.</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman';">Name: Frank Bedu-Addo, Ph.D.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman';">Title: President and Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br/>
      </div>

      <div style="font-size: 10pt;"><br/>
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20058659_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none; font-size: 10pt;">
    <div style="text-align: right;"> <font style="font-size: 10pt; font-weight: bold;">Exhibit 99.1<br>
      </font></div>
  </div>
  <div><font style="font-size: 10pt;"><br>
    </font>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7591e1b8ddcf428c86845cad527d0b44" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze9662174a37c4f28a0ea6e3b2f36cc9d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more
                  active in killing cancer cells</font></div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze0fb8557b57b4371b013867e2250c994" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
              <div style="font-family: 'Times New Roman'; font-style: italic;">PDS01ADC promotes stem cell-like killer T cells and memory T cells that self-replicate and are therefore capable of potent and long-lasting anti-tumor activity</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PRINCETON, N.J., November 10, 2025</font><font style="font-size: 10pt;"> &#8211; PDS
          Biotechnology Corporation (Nasdaq: PDSB) (&#8220;PDS Biotech&#8221; or the &#8220;Company&#8221;), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced positive clinical and translational data
          presented at the 2025 <font style="font-family: 'Times New Roman'; font-style: italic;">Society for Immunotherapy of Cancer (SITC) </font>Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong
          clinical activity of the Company&#8217;s investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The studies were performed as part of PDS Biotech&#8217;s collaborative research and development agreement (CRADA) with the National Cancer Institute (NCI) Center for Cancer
        Research (CCR). Presentations at SITC 2025 included one rapid oral abstract, recognized among the top 150 abstracts of the meeting, and two poster presentations.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The data presented at SITC further validate the scientific underpinnings of our immunotherapy platforms and confirm that our development approach is achieving the
        intended immunological and clinical effects,&#8221; said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. &#8220;These findings provide a deeper understanding of how our immunotherapies are generating such promising results in
        advanced cancers. The ability to measure and model these immune effects enhances confidence in our programs and supports our regulatory strategy to advance these novel, investigational immunotherapies toward commercialization as efficiently as
        possible for patients with difficult-to-treat cancers.&#8221;</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS0101) Data Highlights</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Rapid Oral Abstract Presentation Number:</font><font style="font-size: 10pt;">&#160;<font style="font-family: 'Times New Roman'; font-style: italic;">37</font></font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: Baseline and </font><font style="font-size: 10pt;">early changes in serum
          proteomic profiles predict anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Authors: </font><font style="font-size: 10pt;">Megan Lynch, Meghali Goswami,
          Charalampos Floudas, Julius Strauss, Yo-Ting Tsai, Jennifer Marte, James Gulley, Jeffrey Schlom, Renee Donahue</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Recognition:</font><font style="font-size: 10pt;"> Selected among the Top 150 abstracts
          at SITC 2025</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Key findings:</div>
      <table cellspacing="0" cellpadding="0" id="z64953d04bd53441ea91ea0354d631e9d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Analysis of <font style="font-family: 'Times New Roman'; font-weight: bold;">50 patients</font> with advanced HPV16-positive cancers treated with the combination of PDS0101, PDS01ADC and an immune
                checkpoint inhibitor showed strong and broad immune activation, with increases in multiple critical pro-inflammatory cytokines that are essential in recruiting T cells and enhancing their potency.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z95b176fdbbec4fe28f0b74716cbcf097" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Quantitative measurements of various immunological proteins in the blood were found to predict clinical benefit with good accuracy.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z64b413f965f642d3ac3e29b8ded3f435" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">The data supports continued evaluation of these biomarkers obtained by blood sampling, and prospective validation of the developed predictive models in future clinical trials.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">These translational findings further reinforce the strong clinical activity seen with PDS0101 combinations across three phase 2 trials. By establishing a clear link
        between specific immune signatures and clinical response, the data provide strong rationale for future biomarker-guided optimization of PDS0101-based immunotherapy combinations.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PDS01ADC (IL-12 tumor-targeting immunocytokine) Data Highlights</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Abstract Number: </font><font style="font-size: 10pt;">47</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: </font><font style="font-size: 10pt;">A tumor-targeting IL-12 immunocytokine
          therapy in patients with advanced solid tumors increases peripheral natural killer (NK) cells with phenotypes associated with increased tumor cell lysis</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Authors: </font><font style="font-size: 10pt;">Stephanie Pitts, Nicole Toney, Jennifer
          Marte, James Gulley, Jeffrey Schlom, Renee Donahue</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Key findings:</div>
      <table cellspacing="0" cellpadding="0" id="zba1cf7bd00f24c98a97483ffbbfa9425" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">PDS01ADC monotherapy promoted generation of multi-functional NK cells that were associated with induction of a clinical response in advanced treatment-resistant patients with solid tumors.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8374775a24e94d35ab0caed5bfc4cbfd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Specific types of NK cells associated with effective killing were seen to increase in advanced cancer patients with solid tumors upon treatment with PDS01ADC, and the increases were associated with
                an improved clinical response.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3a60ee82c46e4acf8f0ba9f6da336044" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">Several types of NK cells associated with poor anti-tumor response were seen to decrease with PDS01ADC therapy, and these decreases were associated with an improved clinical response.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Collectively, these results demonstrate immune reprogramming of NK cells toward killer phenotypes upon treatment with PDS01ADC and provide mechanistic support for
        PDS01ADC-based combination immunotherapy strategies.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Abstract Number: </font><font style="font-size: 10pt;">168</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: </font><font style="font-size: 10pt;">Increases in peripheral memory T cells
          with self-renewing properties in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy</font></div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Authors: </font><font style="font-size: 10pt;">Meghali Goswami, Carolina Celades,
          Christine Minnar, Asma Khelifa, Lisa Poppe, Dara Bracken-Clarke, Nicole Toney, Megan Lynch, Jennifer Marte, Sofia Gameiro, James Gulley, Jeffrey Schlom, Renee Donahue</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Key findings:</div>
      <table cellspacing="0" cellpadding="0" id="z29bfa8bd285142cfb97676d37aea8cbf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">PDS01ADC monotherapy increased the quantity of stem-like memory, CD8 (killer) and CD4 (helper) T cells that had self-replicating properties in patients with advanced solid tumors</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zb6c7c13b218e438b8592e81d022a1e97" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In 28 patients with advanced solid tumors, increases in stem-like T cells was associated with stabilization of disease</div>
            </td>
          </tr>

      </table>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">These translational findings show that PDS01ADC promotes specific types of self-replicating T cells that enhance the durability of anti-tumor immunity.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;The immune signatures we observed with both PDS0101 and PDS01ADC deepen our understanding of how these therapies generate a powerful anti-tumor immune response. We are
        seeing broad immune activation, including early natural killer cell responses and expansion of durable, stem-like memory T cells, features that are critical for long-term tumor control,&#8221; said Kirk Shepard, M.D., Chief Medical Officer of PDS
        Biotech. &#8220;The translational data presented at SITC, including early immune biomarker signatures, HPV ctDNA dynamics, and coordinated NK and T cell activation validate our platforms scientifically. These insights will also help us design future
        studies and combination approaches that fully leverage each therapy&#8217;s unique mechanism of action.&#8221;</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Building on these findings, PDS Biotech continues to advance the development of PDS0101 and PDS01ADC. The company is developing PDS0101 in combination with Keytruda&#174;
        (pembrolizumab) in a phase 3 clinical trial of HPV16-positive recurrent/metastatic head and neck cancer. In parallel, PDS Biotech is advancing PDS01ADC via NCI-led Phase 2 clinical trials under PDS Biotech&#8217;s CRADA with the NCI in metastatic
        colorectal cancer, cholangiocarcinoma, biochemically recurrent prostate cancer, and castration resistant and castration sensitive prostate cancer. Collectively, these data presented at SITC 2025 strengthen the scientific foundation of the Company&#8217;s
        immunotherapy platforms and support continued progress toward future regulatory and clinical milestones.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About PDS Biotechnology</div>
        <div style="font-size: 10pt;">&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal
        clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech&#8217;s lead investigational targeted immunotherapy PDS0101 (Versamune&#174; HPV) is being developed in combination with a standard-of-care
        immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various
        cancer indications in combination with standard of care.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For more information, please visit www.pdsbiotech.com</div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward Looking Statements</div>
        <div style="font-size: 10pt;">&#160;</div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and
        Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the &#8220;Company&#8221;) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events,
        results of operations or financial condition, or otherwise, based on current beliefs of the Company&#8217;s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include
        statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221;
        &#8220;forecast,&#8221; &#8220;guidance&#8221;, &#8220;outlook&#8221; and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual
        results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company&#8217;s ability to protect its intellectual property rights; the Company&#8217;s anticipated
        capital requirements, including the Company&#8217;s anticipated cash runway and the Company&#8217;s current expectations regarding its plans for future equity financings; the Company&#8217;s dependence on additional financing to fund its operations and complete the
        development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company&#8217;s operations or require the Company to relinquish rights to the Company&#8217;s technologies or product candidates;
        the Company&#8217;s limited operating history in the Company&#8217;s current line of business, which makes it difficult to evaluate the Company&#8217;s prospects, the Company&#8217;s business plan or the likelihood of the Company&#8217;s successful implementation of such
        business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune&#174; HPV), PDS01ADC, PDS0103 (Versamune&#174; MUC1) and other Versamune&#174; based product candidates; the future success of such trials; the successful
        implementation of the Company&#8217;s research and development programs and collaborations, including any collaboration studies concerning PDS0101 (Versamune&#174; HPV), PDS01ADC, PDS0103 (Versamune&#174; MUC1) and other Versamune&#174; based product candidates and the
        Company&#8217;s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company&#8217;s product candidates; the success, timing and cost of the Company&#8217;s or its
        partners&#8217; ongoing clinical trials and anticipated clinical trials for the Company&#8217;s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the
        Company&#8217;s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company&#8217;s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of
        interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company&#8217;s ongoing clinical trials; any Company statements about its understanding of
        product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company&#8217;s ability to continue as a going concern; and other factors,
        including legislative, regulatory, political and economic developments not within the Company&#8217;s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and
        should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and
        Results of Operations&#8221; and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company
        undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Versamune&#174; is a registered trademark of PDS Biotechnology Corporation.</div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
          <div> <font style="font-weight: normal;">Keytruda&#174; is a registered trademark of Merck Sharp &amp; Dohme Corp. (a subsidiary of Merck &amp; Co., Inc.)</font></div>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z48a4c06aff8d4f9aa3d0e460da17c0c0">

              <tr>
                <td style="width: 50%; font-weight: bold;">Investor Contact:</td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Mike Moyer</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">LifeSci Advisors</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Phone +1 (617) 308-4306</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Email: mmoyer@lifesciadvisors.com</u></div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Media Contact:</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">David Schull</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Russo Partners</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Phone +1 (858) 717-2310</div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50.00%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Email: david.schull@russopartnersllc.com</u></div>
                </td>
                <td style="width: 50.00%;">
                  <div>&#160;</div>
                </td>
              </tr>

          </table>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pdsb-20251110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<xs:schema targetNamespace="http://pdsbiotech.com/20251110" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:pdsb="http://pdsbiotech.com/20251110" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20251110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pdsb-20251110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>pdsb-20251110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>pdsb-20251110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://pdsbiotech.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pdsb-20251110.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://pdsbiotech.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PDS BIOTECHNOLOGY CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001472091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-4231384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">303A College Road East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">208-3343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00033 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PDSB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20058659_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pdsbiotech.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20058659_8k.htm">ef20058659_8k.htm</File>
    <File>pdsb-20251110.xsd</File>
    <File>pdsb-20251110_lab.xml</File>
    <File>pdsb-20251110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20058659_8k.htm": {
   "nsprefix": "pdsb",
   "nsuri": "http://pdsbiotech.com/20251110",
   "dts": {
    "inline": {
     "local": [
      "ef20058659_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "pdsb-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pdsb-20251110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pdsb-20251110_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20251110to20251110",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20058659_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251110to20251110",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20058659_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://pdsbiotech.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-25-041286-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-041286-xbrl.zip
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MYY_^!3KA);#7HRNE%"[L[M?E_[LG$Y@UDD@H6$N%%D0RU!]Q*@TY!K8/Z@[
M%N/I^^]W+_VHY)B3(.+09Q2!(D5E)&%'>D+@?408J]Z+L=3C8_U;MX+E _FB
M_V5F2,(T(S+*H$[UU,@/5C0NX>T@O8[L.[>??#S(T\/:E[+X(&?5-$JH3!.
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M) _Z#1KFBFV5:?TYEKOD?07KJT=^?4+#@-LFX;;%/4IL8O  %IR'GD5P@[1
MF7S\<=NKV(3;_EP+6??Q2TU=$Q.M.-G;:7:&^/ *M+LSDC'R!^J2D?3]HZ\D
M_<;S*K#R3 EI+Z3?]F(F=7F.@BFB*FHSA-F K.(J(VHAI"(R!/@#0T#&Z*[1
M=9K<Y@-I$HQDF(5D",PF$1=YYH4;6+<KE7C!!UP<OS%G!H%,-W/WE4>X:@.C
M@?0<R61U&8>3'<[0 PQ6,U9TO>J(S^(8TO2X:UX;I;7=J-C)&KS=D]%1-?ND
M6G6+1C5F0\/0"5W7-%S.+<>D 2<Z-USL<NHX%FN0TO%H^[4QMC:<@[R+:VZB
MW%G<\KN+=?;"#32Q!Y2PDL#$4KAR .3#(S F@7SB1)F6XXRK6@!E&125]]2(
MPO)6)[[DRJFQHJD<_%; T')+Q0 RE*3\1F2<S1 2SFX((53=+R,;R6N"&$E9
M5H1%V3K[UMPE,_NV3F8M]"] 4KE'T%F"9MNE^0&/YSP8LO$<_M)1^WJJP](A
M_=<YA[\" :43\./EQ>D%N>8?4TZ^R;R3F9> 1IRD,B4@'\RZ+>:DZ*O\,KN-
M8!%[Z\:8]3^"+UH@/VDDS"5Z271+IMF\D*ZM0I4I(A&NUW-#ZFZ)\IN^D$;R
M@-,\]7DOH^XMRMY!COEL_M:5Z2>]G ^1U]+Q]^_.7 E_D?I](H_<9JTM:6J/
M97C+Z%!?0*8 M*"_UVF[X"NU*R4>),7.93KTP@'>/:1.0!;W6<6P4Z^GJ'N7
M$ _:8#8&84% ;LC\RQ2D%P&)1>(82)6J/)M$2JL;(+I(2)]QI)(PE12+5!_P
MA9&<S' I>Y+L$GK-E:!1]TL]/36GGU#!\ZD2ESWIP$[DJI.1R@WJRFORTDI;
M.(KCL53J.9?2L86DPE^"5>2.H 'LGTA=@B5D5UQC*<PQ1D,NA:+(AIF:9B 2
M*>IYFL%,8#I\,HJ(D/-($\!-A9+9W$&7$S>@[U4RMM3T9CF((K[A65[F.P&$
MGR_^&SM:#JO/)<+$W+1@Y72L8P6(R#,0AC<\VEOJHVA$IWGR#?3VHM71<?=!
MBO#REOP!M+W_'0,:PNE*@GHX]1P!(Q_-%FZ>',"^D!>J,1!Q*2\4-&FF#$0@
M<N3[K7*-9D=-H":HBK/[H%0S$6]8D0<QES<9N#49Z/^X,K!V<Z \S2 #?04/
M*_?IU@3CTPVP;:;$UJJ\.MULI(HYNJ@HHQIWU29;VD&+V[2^,,H\6;-9ZT']
MI4Y?9*UWV:J(TRHOZ.99%B!MFF1AG[W*)#?1X1J'[XJ03OFP2(]O<>IE_NRW
MO+5'-A=<"B48=V[M[4<9-^V1%XDPK@2@.!KSE( $7H'R LW/</[9\S?T_IV$
M*%;B]9AG-!4CJ;)O/9J[:=\_>05>?GE?\&S[PS#W[)$M@HI;9WEHZ+KM.;;_
M;S[Q?0VW!OEPYU :&@=M\J2+*+Z;Y6N(O$;R5Z6X@;EV69IKQ\H"6_*%/$H!
M?J.\/P'E8=UZ(ZHEK'2!@%(DXPBH)Q&IG%N*NDAQX\2NI"\F@TW2)R)BY3GI
MJ9]D0/+*]=E5]>]?S/;\WMQ6;T&?9PCZO,@5H] ER<=IP^M-5[E-G<<Y'NNW
MKA;QY#_&(BT=.,VR(_96!:+9.)HB2L;J5R9DBD1Q&:D<)N H@VE @0P!P# !
M'Y HE$Y+Z&BV+U3^=UE1NC#',;15W8(9/4A2F 5[6:?FSVZRFO;SJP_-NI.S
MDTSLPX[QO')D);7=<RWGMN_^^CZPO)7;N1XPM>?6HJ3:W5E6NY^B63W_;!KJ
M/A^GG:? [:S-K=TVX,TOK6EG;70*TN(;^LC96#MB+-E#%X/6<:OYA8<_!1T^
M[P+(LP.=M8A]P^C#,:JR\#M(VOCJ]VQ45*L[$#Q<NB*JB>?R,7;&\V6[;6ZW
M,AGN.[LEN?83.O,_IO/ G^"I?N.G+7\G3/UN6#Z,#O\?4$L#!!0    ( 'I$
M:EN.)WM )QH  '&'   5    968R,# U.#8U.5]E>#DY+3$N:'1M[3UI<]M&
MEM^G:OY#CU*;D6I)AI=X2+9K9,G.:&PK7LLS6_NQ 33(CG %#4AF?OV^][H;
M:("@+"=6+,=RY:#!1A^OWWWQR;J(HV=__0MC3]:"!_0)/A>RB,2S)S_H_YN'
M?^OWV6OIBT2)@!7I$7N>ISS(9; 2>@3].4O],A9)P?Q<\ )&EDHF*V<L>_ON
MIU!&@HT/!Z/A8#0XG$PFS@2G:;;)Y6I=L-%R><CZ;#P<'[KO]_MZPS^8'3_Q
MTF##O)6?1FG^=.^[D/[L,55L(O%T+TR3HA_R6$:;(_;W]S(6BEV(&_8NC7GR
M]V-&WROYJSABHV%6'+-"?"CZ/)*KY(A%(H0G-/,1^VY(?X[W]/KX8F,19Y*]
M9[ _?*B'!O+:0G&=LR15:Q[ 6^;#'J/5GNX!; N15SM?"P3#$9MF'ZH]Y"MO
M?]AC^,_!,?.X?[7*TS()^IW?NT?1DQ^SF.<KF?3Q9$>,ET5:/<KU<OJ9E^:!
M@ EC$<@RACTG8AM6>_94<$"[:W=-FI& <1NP]+0WYK1>&@7PRHL/:^G)@BV7
M@]$3+W]F,<2 ]<D/%J;.)_SPD6NIIW+NIW%#NT]C(?C)&-5UOK=GE^RY3 OA
MKQ.XNM6&G20)W*0/D[W/>:(B7L@TX1$[XP5GE^OT!NGHLLA3^-]Y')?TFO1A
M!$\"=AK)A/YRXA?R6A8;EH8,%AF.AB,:0)]/SD[9VUPH/$G >,$NS]^?$H75
M8&R#X#8@NN#7G(-[0-J^B"*5<1]V_'1ON$=_SW@0V+_+X.G>K_/#Y4B,O$40
M^.%TO/ 7L\7TT.?!X7@>#+WI%%Z+N%)/]\XNW[Y\+57Q'N?^[71](X-BC7\9
M_M>=B5S_<;@3G#!_YOX=GP1V3W:)!:YW+?(";\0N4Z39I^/.WK/OOUN,Q[-C
M8,;!1Q?6I-NYL'O@GTM5R'"SFYZ=-=J(\-&]X]@C)@M8RX<)F[BLBA)XM0)D
M5JQ8 _[%953(#%!&-C#:DS!G?B5RQ;(<.)!?P'# *XODO /)_33V9$(KX>"<
M9YLF<EJ$;0$2'N0=EPV/$=_^4)(0R]EL/)I/^63N3\/Q@@\%GXF)-PXG,]]?
M!H\D<=\D\3DH0&]UK/'BXX+O4RFJ8N2YR/)TE?-8,4#[,@>ZN))1)'*V?_'J
M0&,<G)1EJ5)"*>:O>0Z$(W) '.E; N17 LDE9G&:B_;A\0_1&A!H0K.C$/(Y
MB*E<+[ EC[\22AN&WN+P<.[!/]/)?.0-1Y/%;"[&X\.AOUP^"I\_A?"I2 4(
M)09=2\%L@.F($?U( N(;>GEOB 7UI%@ (6RJ1T0D2D1A'\@-9@6;AH;QG,@F
M%R&0#5!$1K@'XBB#=8#D<4P$JEH?T*A HN%)(?M%"9-7TNM!$,T.95?CY1=A
M>&U-^=WYQ>F+]S]=]-C%X%\#^&]Z+6(/KFT$9H[6734/^HA%AL@\&AVCPN "
MN*F%GZ9YEN9:B]B_X"K@OQSA&\\/V#Y1P_#84=WI"4P)EXKZB1EPFL893S;F
MRX,>XPPT( 'HR5=6TS$:"FHM.!9.[I=H6*/R@BH3H%6,: .J$DU-;PFF-H3!
M!5ALHM (BSBL#$]6/2"X@&_@"VU,!,C])3'P6GF"EXJ&6A: B>&")'--!%R=
M;/!M^'XJ/5ZFOA0%'C8W)HP% Q#.J98J^VB2'%CS#(RB$C;X1@@DH@%[#YLQ
MNZ/-*[8&9(G(7Z!!U ]R.&T"= SR+I$JUE!R-$HB:?$ABSC(-$4&E7OX3B43
M@>!<ZVA^K$ B7@N@[96%XC_?_F<TZ^NK = U[]DUQ23<7 )('/6VYM O^9LB
MO9)PW9:!#3K%[)>G>;T27@IJ]A)&W@!+9)G($7\1?T"!YWEA]'27; B$(/<B
M[A&] 8;BO?+<7Q.0 @$ 2C/R)?%5+@1]VC]]=W)V<@#RM%C3I5Q8R!GT.4\
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M7[4__@]02P$"% ,4    " !Z1&I;16O#5Y02  #6<0  $0
M@ $     968R,# U.#8U.5\X:RYH=&U02P$"% ,4    " !Z1&I;CB=[0"<:
M  !QAP  %0              @ '#$@  968R,# U.#8U.5]E>#DY+3$N:'1M
M4$L! A0#%     @ >D1J6X#]SP9$ P  0 \  !$              ( !'2T
M '!D<V(M,C R-3$Q,3 N>'-D4$L! A0#%     @ >D1J6TZX63)["   ,58
M !4              ( !D#   '!D<V(M,C R-3$Q,3!?;&%B+GAM;%!+ 0(4
M Q0    ( 'I$:EMJ9,+_W 4  /8^   5              "  3XY  !P9'-B
G+3(P,C4Q,3$P7W!R92YX;6Q02P4&      4 !0!' 0  33\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ef20058659_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pdsb-20251110.xsd" xlink:type="simple"/>
    <context id="c20251110to20251110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001472091</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20251110to20251110"
      id="Fact_e0bcc38d2a8a4bc3acdc692cf0ae330e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20251110to20251110"
      id="Fact_5502d1e6007844bc991aa05d7f129030">0001472091</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20251110to20251110"
      id="Fact_e54d3a45ce9949d587f75ef1e7efb576">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20251110to20251110"
      id="Fact_6364f24e2e1641e1a3ccb06a64a841ef">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20251110to20251110"
      id="Fact_1a08603f19f04a71b4a1d2d6e8944b4e">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20251110to20251110"
      id="Fact_dd274b78983b49359076c07a6f89b407">PDS BIOTECHNOLOGY CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20251110to20251110"
      id="Fact_69145a50a6174093a14517c915e6c1ab">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20251110to20251110"
      id="Fact_a90f95bb935a4873baa78fa1bfc447ac">001-37568</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20251110to20251110"
      id="Fact_242bc1dc9e8d4b7186efc842e4796bc2">26-4231384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20251110to20251110"
      id="Fact_587ffb2303ea424fade7f064d0d47ab2">303A College Road East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20251110to20251110"
      id="Fact_4b61fc3e787f49f1a931c4ce76b9a457">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20251110to20251110"
      id="Fact_80e11e4c4ec6486b8574686dfe205d2d">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20251110to20251110"
      id="Fact_41f4b7b9ad6d4d25be9dba57e56aa42d">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20251110to20251110"
      id="Fact_b54f2c46de8b4fe9b93f315139cd17b1">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20251110to20251110"
      id="Fact_1b1765365f6a4b4e8e7c7efc1a24685e">208-3343</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20251110to20251110"
      id="Fact_29cf338191254c848c70378781b61e94">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20251110to20251110"
      id="Fact_b250b94f7ab94587bd5ed1fbc2e9dd22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20251110to20251110"
      id="Fact_3b0aa04173174dc184247bb5fe005793">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20251110to20251110"
      id="Fact_db851a4c723e421499620defaa25ebcf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20251110to20251110"
      id="Fact_37811586ca634ba096608af85746e495">Common Stock, par value $0.00033 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20251110to20251110"
      id="Fact_89acfbe53ae54e8ca5a2eb660ef84a1b">PDSB</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20251110to20251110"
      id="Fact_cff6f77327ee463cbea0e2717ec664dd">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
